1. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide
versus placebo and exenatide in type 2 diabetes (AWARD-1). Abstract #919.
Presented at the 49th European Association for the Study of Diabetes
(EASD) Annual Meeting. 23-27 September 2013, Barcelona, Spain.
2. Van Brunt K, Reaney M, Yu M, Lakshmanan M, Curtis B, Mitchell B.
Patient-reported outcomes with dulaglutide, exenatide, or placebo
(AWARD-1) Abstract #985. Presented at the 49th European Association for
the Study of Diabetes (EASD) Annual Meeting. 23-27 September 2013,
Barcelona, Spain.
3. Centers for Disease Control. National Diabetes Fact Sheet-2011. Available
at: http://www.cdc.gov/diabetes/pubs/pdf/ndf...
[http://www.cdc.gov/diabetes/pubs/pdf/ndf...]. Accessed on:
February 22, 2012.
4. International Diabetes Federation. Diabetes Atlas, 5th Edition: Fact
Sheet. 2012.
5. International Diabetes Federation. Diabetes Atlas, 5th Edition: What is
Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes
[http://www.idf.org/diabetesatlas/5e/what-is-diabetes]. Accessed on:
February 22, 2012.
6. Speight J. Assessing patient satisfaction: concepts, applications and
measurement. Value in Health, 2009 8(Suppl 1):S6-S8.
Refer to: Candace Johnson, +1-317-755-9143, johnson_candace_a@lilly.com[mailto:johnson_candace_a@lilly.com]
(Logo: http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...] )
